Aura Biosciences, Inc. Logo

Aura Biosciences, Inc.

Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.

AURA | US

Overview

Corporate Details

ISIN(s):
US05153U1079
LEI:
Country:
United States of America
Address:
80 GUEST STREET, 2135 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aura Biosciences, Inc. is a clinical-stage biotechnology company developing a novel class of targeted cancer therapies. The company's proprietary Virus-Like Drug Conjugate (VDC) platform uses Virus-Like Particles (VLPs) to selectively target and destroy solid tumor cells while aiming to preserve healthy tissue. Aura's initial focus is on indications with significant unmet medical needs, particularly in ocular and urologic oncology. Its lead clinical program is being evaluated as a potential first-line treatment for early-stage choroidal melanoma, a rare eye cancer where current treatments often result in vision loss.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aura Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aura Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aura Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD
Tyra Biosciences, Inc. Logo
Biotech developing precision FGFR medicines for cancer and genetic disorders.
United States of America
TYRA
UCB Logo
UCB
Biopharma firm developing treatments for severe neurological and immunological diseases.
Belgium
UCB
Ultragenyx Pharmaceutical Inc. Logo
Develops and commercializes novel therapies for rare and ultra-rare genetic diseases.
United States of America
RARE

Talk to a Data Expert

Have a question? We'll get back to you promptly.